source
- FDA grants accelerated approval to AstraZeneca's oral SERD for breast cancer despite advisory panel oppositionFDA granted accelerated approval to AstraZeneca's oral selective estrogen receptor degrader, Camizestrant, for a specific group of breast cancer patients. The approval was issued on Friday even th…
- Novo Nordisk halts two late-stage ziltivekimab heart trials after futility findingNovo Nordisk announced it has stopped work early on two additional late-stage clinical studies of its IL-6 inhibitor ziltivekimab, which was being evaluated for heart disease. The decision followe…